ABSTRACT: Human immunodeficiency virus (HIV-1) is generally transmitted by parenteral contact with infected body secretions. Although extensive epidemiological data and familial studies have failed to provide any conclusive data that saliva may act as a vehicle for transmission of AIDS, both professional and public anxieties remain. The present study, as well as others, suggests that salivary secretions may act as inhibitors of HIV-1 replication in vitro. In our study, the inhibitory activity was determined to be associated mainly with secretions obtained from the human submandibular-sublingual glands. Human submandibular-sublingual (HSMSL) and parotid (HPS) salivas were collected and tested for their ability to modulate the replication of HIV-1, using a plaque assay on HeLa/CD4+ cell monolayers. Initial results examining freshly collected salivary samples from ten individuals confirmed the results previously obtained by Fox et al. (1988, 1989). An average plaque reduction of -66% was obtained with HSMSL, in contrast to 34% reduction obtained with HPS. Titration of the inhibitory activity in HSMSL showed detectable levels at a 1:500 dilution. Comparison of inhibitory activity of dialyzed and lyophilized saliva to fresh saliva indicated little difference between the two samples when filtration occurred after the addition of HIV-1. However, the effect of filtration was significantly diminished in the lyophilized samples. Electron microscopic examination of the saliva-HIV incubates revealed the aggregation/entrapment of virus particles by salivary components. These results suggest that human salivary secretions (with HSMSL > HPS) may have a role in modulating the infectivity of HIV-1.
INTRODUCTION
The human immunodeficiency virus (HIV-1) has been identified as the etiologic agent of acquired immunodeficiency syndrome (AIDS). AIDS was originally classified as a sexually transmitted disease; now, however, the prevalent mode of transmission involves direct parenteral contact with infected body secretions. The presence of infectious virus has been demonstrated in blood and blood products, semen, urine, and, infrequently, saliva (Ho et al., 1985; Groopman et al., 1984) . Symptomatic HIV-1-positive individuals frequently have oral mucosal and gingival lesions such as gingivitis and candidiasis, which could increase bleeding into the cavity, thereby increasing the probability of releasing HIV-1 particles into saliva. Epidemiological data and intensive familial studies have failed to provide any conclusive data that saliva may act as a vehicle for transmission of AIDS (Klein et al., 1988; Mann et al., 1986; Friedland et al., 1985) . Because of these observations, it has been postulated that salivary secretions may possess the ability to neutralize infectious HIV-1 particles.
A number of studies have indicated that saliva may inhibit HIV infectivity. Fultz (1986) demonstrated that whole saliva has the capacity to inhibit the in vitro replication of HIV in phytohemagglutinin-stimulated peripheral blood lymphocytes. This inhibition was demonstrated by incubating HIV particles with whole saliva, followed by filtration prior to assay. Inhibition of HIV infection was measured as a reduction of the level of reverse transcriptase activity. It was shown that filtration of the saliva before addition of the virus eliminated this inhibitory effect. Fox et al. (1988 Fox et al. ( , 1989 (Block and Brotman, 1962) , whereas parotid saliva (HPS) was collected using a CarlsenCrittenden apparatus (Curby, 1953) . After discarding the first 1 ml of saliva, approximately 10 ml were collected into chilled tubes containing 2.5 ml of 0.1 M Tris-HCl, pH 7.5, with 2% disodium ethylenediaminetetraacetic acid (EDTA) and 5 mM phenylmethanesulfonylfluoride (PMSF) to minimize protease and glycosidase degradation. Samples were centrifuged at 12,000 x g at 4°C for 30 min then dialyzed and lyophilized as previously described (Levine et al., 1978 Electron Microscopy. The ability of HSMSL and HPS saliva to entrap HIV-1 particles was examined in vitro, using transmission electron microscopy. To increase the chances of locating HIV-1 particles, tenfold concentrated virus samples were obtained by filtration of the infected cell culture supematant through Centri/ Por concentrators (300 kDa cutoff; Spectrum Medical Industries Inc., Houston, TX). The concentrated virus particles (in 100 ,ul RPMI 1640 containing 10% FBS) were added to an equal volume ofthawed saliva samples in 0.5-ml microfuge tubes and incubated for 2 h at 37°C. To localize the virus particles, the saliva-virus mixtures were then transferred to wells of a Dot Blot apparatus and filtered through a Zeta-Probe membrane (0.45 gm porosity, Bio-Rad Laboratory, Richmond, CA). After washing the wells with media, the adherent material was fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2, and filter dots cut into four identical pieces. The pieces were postfixed in 1% OSO4 in 0.1 M s-collidine buffer, en-block stained with 1% uranyl acetate in 0.1 M maleate buffer, pH 6.0, dehydrated in a graded series ofethanols, and embedded in Epon mixture. Ultrathin cross sections of the filters were cut on an Ultracut-E ultramicrotome equipped with a DuPont diamond knife and double stained with uranyl acetate and lead citrate. The presence of virus particles entrapped in saliva within the filters was determined and photographed using a Hitachi H-600 transmission electron microscope.
RESULTS AND DISCUSSION
In agreement with earlier studies, our data demonstrate the ability of salivary secretions to inhibit HIV-1 replication in vitro. Submandibular-sublingual saliva was shown to have the highest inhibitory activity; however, significant levels were also present in some parotid secretions. Table 1 shows that HSMSL inhibitory activity ranged from 44 to 100% with an average of 66.3 ± 17.5%, whereas HPS from the same individuals averaged 34.7 ± 29.3%. These data support the previous observations of Fox et al. (1988 of Fox et al. ( , 1989 ) that Figure 1 . Significant levels of inhibitory activity were detected at a 1:500 dilution of freshly collected HSMSL. This level was higher than that detected by Fox et al. (1989) or Archibald and Cole (1990) . This could be related to the physical number of infectious particles used in each type of assay. The present assay uses severalfold fewer virus particles than do the previous two assays, which could account for the increase in the inhibitory titer of HSMSL. Similar to the studies of Archibald and Cole (1991) , the plaque assay used in this study assesses inhibition through the visualization of syncytia. However, the present assay differs in that the target cells were monolayers of HeLa-CD4+ and syncytia visualized using enzyme-linked immunological techniques. The ability to use monolayers enables the visualization of a single infectious center, resulting in the ability to quantitatively assess data from inhibition assays.
The previous studies did not address the mechanism(s) by which saliva inhibits HIV replication. The fact that filtration reduces salivary HIV inhibitory activity indicates that it is possible that aggregation and/or entrapment of virus particles may be one possible mechanism. The data presented in Table 2 , showing the effect on inhibition of prefiltration and postfiltration of HIV-1 after mixing with saliva, are consistent with this mechanism. Whole as well as glandular salivas have been shown to form precipitates on freezing (Soderling, 1989) . It has been suggested by Dawes (1963) that the precipitate is a result of Caproteinates formed following freeze/thawing the saliva. Treatment with disodium EDTA was found to prevent precipitation. The present procedure for lyophilization of HSMSL and HPS involves treatment with EDTA during the collection and initial dialysis. This should result in a reduction in the formation of Ca-proteinates during the reconstitution of lyophilized HSMSL. The data obtained from fresh HSMSL (Table  2 ) demonstrate a significant loss (83 vs. 14%) of the inhibitory activity when saliva was filtered prior to addition of HIV. This loss appears to correlate with the loss of particulate material in the saliva sample. In the lyophilized sample of HSMSL, a detectable loss of activity was also seen but it was not as great as with the fresh sample. This result appears to correlate with the decreased amount of particulates present in the reconstituted sample.
Direct visualization of the ability of these salivary precipitates to entrap and/or aggregate HIV-1 particles was achieved by transmission electron microscopy. Aliquots of frozen and thawed (fresh) salivas were incubated with concentrated HIV-l particles and col- lected on Zeta-probe membranes. After preparation of the membranes for electron microscopy, each membrane dot was cut into four equal quadrants from which five to eight thin cross sections from each were prepared and examined for HIV-l particles entrapped in salivary particulates. At the ultrastructural level, clear morphological differences between the filter retentates of HPS and HSMSL were observed. HPS displayed moderately electron-dense material, consisting of primarily fine granules with a homogeneous size, and tended to form multilamellated configurations (Figure 2a) in the pores of the filter. In contrast, HSMSL saliva appeared as amorphous materials that were composed of electron-dense granular and filamentous components of various sizes (Figures 2b,c) . As can be observed in Figure 2 , transmission electron microscopy revealed the presence of a group of virus particles that were either embedded in (Figure 2b ), or associated with (Figure 2c ), precipitate obtained from HSMSL. These particles demonstrated a morphology typical of mature HIV-1. They had a diameter of 100 to 120 nm and contained the dense core structure and the envelope characteristic of HIV-1 (Smith et al., 1990; Meyenhofer et al., 1987; Epstein et al., 1985) . However, no virus particles were observed in the retentate of HPS (Figure 2 ). These data strongly suggest that one mechanism responsible for the reduction of HIV-1 infectivity after treatment with saliva results from entrapment and/or aggregation of virus particles by salivary secretions. Although the presence of this aggregating ability would account for the reduction of the number of plaques in this assay, other mechanisms for inhibition cannot be ruled out. Clements et al. (1991) gested that proteolysis of HIV-1 surface glycoproteins inhibits virus replication. Human whole saliva contains a number of proteolytic enzymes, most of which are of microbial origin (Nakamura and Slots, 1983) . The presence of proteolytic enzymes in glandular secretions has also been determined (Makinen, 1989) . More recently, studies have indicated that sulfated monosaccharides and polysaccharides interfere with adsorption/penetration of HIV-1 as well as syncytia formation (Bagasra et al., 1991) . Anionic salivary glycoproteins (e.g., salivary mucins) in HSMSL have been shown to contain, in addition to N-acetyl-neuraminic acid, covalently linked sulfate as N-acetylglucosamine-4-sulfate (Levine et al., 1985) .
In conclusion, this study confimned previous results showing a HIV-1 inhibitory activity in salivary secretions. In addition, we have presented direct evidence for the entrapment of virus particles by precipitated salivary components as one possible mechanism for this inhibition. These precipitates are heterotypic complexes that have been shown to contain a number of salivary proteins and glycoproteins. These include, salivary mucins, secretory IgA, lysozyme, peroxidase, amylase, statherin, and detectable amounts of the proline-rich proteins (M.S. Reddy, personal communication; Tabak et al., 1982) . Components present in these heterotypic complexes will next be isolated and tested for inhibitory activity. Further studies will be required to assess the possible role of other salivary components in the inhibition of HIV-1 replication.
